Document is current
Any future updates will be listed below
-
Authors
Liao, Ting-Wei Ernie https://orcid.org/0000-0003-2345-0154
Xu, Lingyu https://orcid.org/0000-0001-6145-8371
Khoshknab, Mirmilad Pourmousavi https://orcid.org/0000-0003-1479-5038
Mather, Paul J.
Bravo, Paco E. https://orcid.org/0000-0002-0022-4376
Desjardins, Benoit https://orcid.org/0000-0003-0693-4982
Nazarian, Saman https://orcid.org/0000-0002-8369-0259
-
Funding
Funding for this research was provided by:
NIH US (1R01HL142893-01)
American Heart Association (23POST909139)
- License Information
-
More Information
Article History
Received: 15 January 2025
Accepted: 31 March 2025
First Online: 6 May 2025
Declarations
:
: This study was conducted in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. All patients enrolled are registered under the Hospital of the University of Pennsylvania Cardiac Electrophysiology Registry.
: Dr. Nazarian is a consultant to Dyne Pharmaceuticals and ADAS software and the principal investigator for research funding from Biosense Webster and the US NIH. The University of Pennsylvania Conflict of Interest Committee manages all commercial arrangements. The remaining authors have nothing to disclose.
